Search Results for keywords:"Justice Department"

The Office on Violence Against Women within the U.S. Department of Justice announced the cancellation of a scheduled meeting for the Task Force on Research on Violence Against American Indian and Alaska Native Women. Originally set for February 10, 2025, the meeting will be rescheduled. The cancellation was noted in a previous Federal Register notice. For further details, individuals can contact Sherriann C. Moore or visit the agency's website links provided in the notice.

The Department of Justice has lodged a proposed consent decree with a South Carolina court as part of a lawsuit against LANXESS Corporation. The lawsuit, filed under the Clean Air Act, claims that LANXESS failed to properly manage and monitor equipment at its Charleston facility to prevent hazardous air pollutant leaks. The proposed decree includes a $650,000 civil penalty and requires LANXESS to perform substantial environmental projects, costing at least $3.545 million, to comply with the Clean Air Act. The public can submit comments on this proposed decree within 30 days, either by email or mail.

Pharmaron Manufacturing Services (US), LLC has applied to the Drug Enforcement Administration (DEA) to become a bulk manufacturer of certain controlled substances. This registration is intended to allow the company to produce materials for clinical trials. Interested parties can submit comments or request a hearing on the application by May 27, 2025, via the Federal eRulemaking Portal. The application was officially filed on February 11, 2025, and no other activities related to these substances are authorized beyond clinical trial production.

The Drug Enforcement Administration (DEA) has decided to revoke the registration of Dr. Kevin Petersen, meaning he can no longer prescribe or handle controlled substances. This decision came after it was found that his medical license in Nevada, where he practiced, had expired and was then revoked, which automatically made him ineligible to maintain his DEA registration for handling such substances. Dr. Petersen did not contest this action by requesting a hearing, leading the DEA to proceed with its final decision. This order will officially take effect on January 29, 2025.

The United States Department of Justice, along with several states, filed a lawsuit against RealPage, Inc. and several landlord companies, claiming they violated antitrust laws. The lawsuit alleges that these companies used RealPage's software to share sensitive rental information to influence and align rental prices, reducing competition and leading to higher rents for tenants. As part of a proposed settlement, Cortland Management, one of the defendants, agreed to stop using RealPage's software and instead use its own revenue management system without sharing sensitive data. The settlement aims to prevent Cortland from engaging in similar anticompetitive behavior in the future.

Fisher Clinical Services, Inc. has applied to the Drug Enforcement Administration (DEA) to register as an importer of certain controlled substances. The company intends to import these substances solely for clinical trials. Other types of uses or commercial sales are not allowed under this registration. Interested parties can submit comments or objections electronically by April 16, 2025, and can also request a hearing on the application by the same date.

The Bureau of Prisons (BOP) has finalized a rule updating regulations for attorney-client visits at BOP institutions. The rule, effective December 17, 2024, clarifies that attorneys can visit clients without appointments at certain facilities that host pretrial detainees, but appointments remain necessary at other institutions. After considering public comments, BOP concluded that no changes were needed to the initial interim rule. The rule ensures that legal visits can happen under both scheduled and unscheduled conditions, depending on the facility's mission, while maintaining the confidentiality required for attorney-client interactions.

The Consortium for Rare Earth Technologies (CREaTe) has updated its membership list by adding AsterTech LLC from Dayton, Ohio. This change was reported to the Attorney General and the Federal Trade Commission as required by the National Cooperative Research and Production Act of 1993. The notifications are meant to limit the antitrust plaintiffs' recovery to actual damages when certain conditions are met. CREaTe plans to continue submitting updates about any further changes in membership.

The National Armaments Consortium (NAC) has submitted new notifications about changes in its membership as required by the National Cooperative Research and Production Act of 1993. This filing aims to limit the damages that antitrust plaintiffs might claim under certain circumstances. The newly added members include companies from various states, such as Air Space Intelligence Federal Inc. and EverGlade Consulting, LLC. Despite these changes, the group's activity plan remains the same, and membership is still open. The Department of Justice published a related notice in the Federal Register on February 28, 2025.

The Drug Enforcement Administration proposes to make seven fentanyl-related substances permanently controlled under Schedule I of the Controlled Substances Act. These substances, identified as dangerous opioids, are currently regulated under a temporary order due to their potential for abuse and health hazards. If this proposal is finalized, it would enforce permanent restrictions and legal penalties on the handling of these substances, which include para-chlorofentanyl and ortho-chlorofentanyl. The public is encouraged to submit comments on this rule by January 29, 2025.